Login to Your Account

Washington Roundup

Tuesday, November 6, 2012
The FDA's Office of Prescription Drug Promotion, Division of Professional Drug Promotion issued a letter to ONY Inc., of Amherst, N.Y., stating that materials on its website are false or misleading because they present unsubstantiated superiority claims for Infasurf, omit important risk information and make unsubstantiated claims for the product.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription